Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03320798
Recruitment Status : Completed
First Posted : October 25, 2017
Last Update Posted : October 25, 2017
Sponsor:
Information provided by (Responsible Party):
CHU de Reims

Brief Summary:
Bullous pemphigoid affects mainly elderly patients. It is often associated with neurologic disorders, which represent a major risk factor of the disease

Condition or disease Intervention/treatment
Bullous Pemphigoid Other: Data record

Detailed Description:
The aim was to determine whether neurologic disorders, especially dementia, influences outcome and mortality of patients with bullous pemphigoid.

Layout table for study information
Study Type : Observational
Actual Enrollment : 178 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients
Actual Study Start Date : October 1, 2013
Actual Primary Completion Date : October 1, 2014
Actual Study Completion Date : March 1, 2015

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
group "Bullous pemphigoid"
Patients consulting at dermatology department of Reims Teaching Hospital for bullous pemphigoid between 1997 and 2011.
Other: Data record



Primary Outcome Measures :
  1. neurological disease [ Time Frame: Day 0 ]
    neurological disease are dementia (Alzheimers disease or other dementia), Parkinson's syndrome and stroke. Diagnosis of dementia was carried out in several ways: after examination by a neurologist or geriatrician, when the Mini Mental State was less than or equal to 17 or in the presence of a demonstrated and clinically evident dementia.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients presenting bullous pemphigoid and consulting at dermatology department of Reims Teaching Hospital (France) between 1997 and 2011.
Criteria

Inclusion Criteria:

  • patients presenting bullous pemphigoid using the following criteria: clinical features typical of BP with presence of at least three out of four well-established criteria of Vaillant et al., subepidermal blister on skin biopsy and deposits of IgG and/or C3 in a linear pattern along the epidermal basement membrane zone by direct IF
  • patients consulting at dermatology department of Reims Teaching Hospital (France) between 1997 and 2011

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03320798


Locations
Layout table for location information
France
Damien JOLLY
Reims, France
Sponsors and Collaborators
CHU de Reims

Layout table for additonal information
Responsible Party: CHU de Reims
ClinicalTrials.gov Identifier: NCT03320798     History of Changes
Other Study ID Numbers: 2016Ao004
First Posted: October 25, 2017    Key Record Dates
Last Update Posted: October 25, 2017
Last Verified: October 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CHU de Reims:
Bullous pemphigoid
neurologic disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Pemphigoid, Bullous
Nervous System Diseases
Skin Diseases, Vesiculobullous
Skin Diseases
Autoimmune Diseases
Immune System Diseases